| Literature DB >> 35410411 |
Deborah Kreher1, Viktoria Korn1, Gerhard Schmalz1, Dirk Ziebolz2, Thomas Meißner1, Rainer Haak1.
Abstract
Aim of this randomized clinical trial was to assess the development of root caries lesions with and without (adjuvant) professional prevention treatment over 24 months. 20 participants with two or three non-cavitated root carious lesions were included (n = 52), whereby lesions were randomly assigned to one out of three groups depending on varnish application (CF: Cervitec F [n = 20], P: placebo [n = 20], DP: Duraphate [n = 12]). All lesions were assessed by quantitative light-induced fluorescence (QLF; QRayCam); following outcome parameters were analyzed: fluorescence loss (ΔF %), lesion volume (ΔQ %µm2) and bacterial activity (ΔR %). Professional tooth cleaning and adjuvant varnish application were performed at baseline, after 3, 6, and 9 months. A follow-up examination was performed 1 year after preventive care with varnish application 24 months after baseline. ∆F showed a significant time effect in CF (p = 0.03), which was not confirmed in post hoc analysis (p > 0.05). For P and DP, no time effect was detected (p > 0.05). ∆Q was significantly higher 12 months after baseline in CF (p = 0.02). In P, a significant time effect occurred (p = 0.01), without significant results in post hoc testing. ∆R showed higher values at baseline vs. 12 months in CF (p = 0.03) and 24 months compared to 12 months in DP (p = 0.02). Professional preventive treatment inhibited the progression of root caries lesions beyond their termination for 12 months, irrespective of an adjunctive varnish application. Preventive measures have a long-term effect on root carious lesions, even 1 year after their termination.Entities:
Keywords: Non-invasive treatment; Prevention; QLF; Root caries; Varnish application
Mesh:
Year: 2022 PMID: 35410411 PMCID: PMC9463297 DOI: 10.1007/s10266-022-00706-8
Source DB: PubMed Journal: Odontology ISSN: 1618-1247 Impact factor: 2.885
Fig. 1Participant flow through the randomized clinical trial (RCT) according to the CONSORT guidelines
Fig. 2Workflow
Patients characteristics
| Total | Group CF | Group P | Group DP | ||
|---|---|---|---|---|---|
| Number of teeth ( | 52 (100) | 20 (38) | 20 (38) | 12 (24) | – |
| Gender ( | |||||
| Female | 24 (46) | 9 (45) | 9 (45) | 6 (50) | 0.88 |
| Male | 28 (54) | 11 (55) | 11 (55) | 6 (50) | |
| Age in years (mv ± sd) | 66.10 ± 9.71 | 66.15 ± 9.79 | 66.15 ± 9.79 | 65.92 ± 9.44 | 0.98 |
| ICDAS II Score ( | |||||
| Score 1 | 38 (73) | 15 (75) | 14 (70) | 9 (75) | 0.82 |
| Score 2 | 14 (27) | 5 (25) | 6 (30) | 3 (25) | |
| Salivary flow rate ( | |||||
| Un-stimulated | 0.93 ± 0.75 | 0.92 ± 0.75 | 0.92 ± 0.75 | 0.97 ± 0.76 | 0.96 |
| Stimulated | 5.28 ± 3.01 | 5.23 ± 3.09 | 5.23 ± 3.09 | 5.41 ± 3.07 | 0.99 |
| Reduced salivary flow ( | 0 | 0 | 0 | 0 | – |
| Salivary buffer capacity ( | |||||
| Low | 3 (6) | 1 (5) | 1 (6) | 1 (8) | 0.87 |
| Medium | 11 (21) | 4 (24) | 4 (24) | 3 (25) | |
| High | 33 (63) | 12 (71) | 13 (72) | 8 (67) |
CRT buffer Test, Ivoclar Vivadent, Schaan Liechtenstein, mv mean value, sd standard deviation]
Distribution of included teeth between groups
| Total ( | Group CF ( | group P ( | Group DP ( | |
|---|---|---|---|---|
| Anterior maxilla | 15 | 8 | 6 | 1 |
| Premolar maxilla | 5 | 0 | 3 | 2 |
| Anterior mandible | 21 | 7 | 8 | 6 |
| Premolar mandible | 11 | 5 | 3 | 3 |
Results for ΔF, ΔQ, and ∆R depending on the time of examination for the total cohort (mean [SD])
| Total ( | |
|---|---|
| Δ | |
| Baseline | – 12.92 (10.48) |
| T1 | – 10.77 (9.93) |
| T2 | – 15.01 (14.27) |
| | |
| Baseline vs. 12 months | |
| Baseline vs. 24 months | 0.99 |
| 12 months vs. 24 months | |
| Δ | |
| Baseline | – 13,453.42 (22,860.31) |
| T1 | – 7787.21 (16,163.49) |
| T2 | – 14,577.82 (31,398.83) |
| | < 0.01 |
| Baseline vs. 12 months | |
| Baseline vs. 24 months | |
| 12 months vs. 24 months | 0.72 |
| Δ | |
| Baseline | 25.92 (35.15) |
| T1 | 19.01 (23.09) |
| T2 | 34.38 (39.66) |
| | |
| Baseline vs. 12 months | |
| Baseline vs. 24 months | 0.99 |
| 12 months vs. 24 months | |
Significant findigs are highlighted in bold (p < 0.05)
Results for ΔF, ΔQ, and ∆R depending on the time of examination for groups (mean [SD])
| Group CF | Group P | group DP | |
|---|---|---|---|
| Δ | |||
| Baseline | – 12.68 (8.95) | – 12.07 (8.78) | – 14.70 (15.30) |
| T1 | – 9.68 (8.64) | – 10.56 (8.10) | – 12.92 (14.43) |
| T2 | – 13.56 (11.92) | – 13.65 (13.51) | – 19.67 (18.80) |
| | 0.05 | 0.09 | |
| Baseline vs. 12 months | 0.53 | – | – |
| Baseline vs. 24 months | 0.99 | – | – |
| 12 months vs. 24 months | 0.17 | – | – |
| Δ | |||
| Baseline | – 10,369.53 (14,495.52) | – 13,338.16 (20,007.63) | – 18,785.35 (36,335.02) |
| T1 | – 5157.79 (8023.49) | – 7163.67 (9705.18) | – 13,208.81 (29,867.32) |
| T2 | – 8473.74 (11,023.93) | – 11,530.35 (18,102.41) | – 29,830.41 (58,792.63) |
| | 0.15 | ||
| Baseline vs. 12 months | 0.05 | ||
| Baseline vs. 24 months | 0.34 | 0.05 | |
| 12 months vs. 24 months | 0.81 | 0.99 | |
| Δ | |||
| Baseline | 22.14 (21.77) | 22.44 (21.10) | 38.01 (62.72) |
| T1 | 16.62 (19.27) | 19.00 (18.23) | 23.00 (35.07) |
| T2 | 27.08 (24.34) | 32.63 (40.69) | 49.48 (55.30) |
| | 0.16 | ||
| Baseline vs. 12 months | – | 0.31 | |
| Baseline vs. 24 months | 0.99 | – | 0.92 |
| 12 months vs. 24 months | 0.10 | – | |
Significant findings are highlighted in bold (p < 0.05)